MAGE A3 antigen-specific cancer immunotherapeutic

Immunotherapy

Volumn 1, Issue 1, 2009, Pages 19-25

  Peled, Nir ^b   Oton, Ana B ^b   Hirsch, Fed R ^b   Bunn, Paul ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

MAGE; Melanoma; Non small cell lung cancer; NSCLC; Vaccine

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 2; LUCANIX; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN 3; MUCIN 1; PLACEBO; STIMUVAX; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANEMIA; ARTHRALGIA; BLADDER CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PAIN; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; FATIGUE; FLU LIKE SYNDROME; HUMAN; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INTERFERON PRODUCTION; KIDNEY CARCINOMA; LETHARGY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PAIN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SWEATING; VACCINE PRODUCTION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MELANOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC;

EID: 77953473376     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.1.19     Document Type: Review

References (43)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002). (Pubitemid 35363648)
2. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunol. 3, 999-1005 (2002).
3. Willimsky G, Blankenstein T: Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141-146 (2005). (Pubitemid 41613441)
4. Morris E, Hart D, Gao L, Tsallios A, Xue SA, Stauss H: Generation of tumor-specific T-cell therapies. Blood Rev. 20(2), 61-69 (2006).
5. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. CD001425 (2005).
6. Eton O, Legha SS, Bedikian AY et al.: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol. 20(8), 2045-2052 (2002).
7. Alexandroff AB, Jackson AM, O'Donnell MA, James K: BCG immunotherapy of bladder cancer: 20 years on. Lancet 353(9165), 1689-1694 (1999).
8. Sienel W, Varwerk C, Linder A et al.: Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur. J. Cardiothorac. Surg. 25(1), 131-134 (2004).
9. Sandler A, Gray R, Perry MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006).
10. Rosell R, Robinet G, Szczesna A et al.: Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19(2), 362-369 (2008).
11. Kim J, Raz D, Jablons D: Unmet need in lung cancer: can vaccines bridge the gap? Clin. Lung Cancer 9(Suppl. 1), S6-S12 (2008). (Pubitemid 351345722)
12. Salerno CT, Frizelle S, Niehans GA et al.: Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase- polymerase chain reaction. Chest 113(6), 1526-1532 (1998). (Pubitemid 28307155)
13. Chambers CA, Kuhns MS, Egen JG, Allison JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
14. Klinman DM: Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin. Biol. Ther. 4(6), 937-946 (2004).
15. Levy F, Colombetti S: Promises and limitations of murine models in the development of anticancer T-cell vaccines. Int. Rev. Immunol. 25(5/6), 269-295 (2006).
16. Brasseur F, Marchand M, Vanwijck R et al.: Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int. J. Cancer 52(5), 839-841 (1992).
17. Brasseur F, Rimoldi D, Lienard D et al.: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer 63(3), 375-380 (1995).
18. De Plaen E, Arden K, Traversari C et al.: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40(5), 360-369 (1994). (Pubitemid 24299325)
19. Weynants P, Lethe B, Brasseur F, Marchand M, Boon T: Expression of mage genes by non-small-cell lung carcinomas Int. J. Cancer 56(6), 826-829 (1994). (Pubitemid 24102748)
20. Boel P, Wildmann C, Sensi ML et al.: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2(2), 167-175 (1995).
21. Bredenbeck A, Losch FO, Sharav T et al.: Identification of noncanonical melanoma-associated T cell epitopes for cancer immunotherapy. J. Immunol. 174(11), 6716-6724 (2005). (Pubitemid 40705633)
22. Miyagawa N, Kono K, Mimura K, Omata H, Sugai H, Fujii H: A newly identified MAGE-A3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-A3-expressing gastrointestinal cancer cells. Oncology 70(1), 54-62 (2006).
23. Miyahara Y, Naota H, Wang L et al.: Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin. Cancer Res. 11(15), 5581-5589 (2005).
24. Pascolo S, Schirle M, Guckel B et al.: A MAGE-A1 HLA-AA*0201 epitope identified by mass spectrometry. Cancer Res. 61(10), 4072-4077 (2001). (Pubitemid 32720973)
25. + T cells from patients with melanoma or renal cell carcinoma. Clin. Cancer Res. 9(3), 947-954 (2003).
26. Valmori D, Dutoit V, Rubio-Godoy V et al.: Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 61(2), 509-512 (2001).
27. Wang XF, Cohen WM, Castelli FA et al.: Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family. Cancer Immunol. Immunother. 56(6), 807-818 (2007).
28. Boël P, Wildmann C, Sensi ML et al.: BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2, 167-175 (1995).
29. Brichard VG, Lejeune D; GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 25 (Suppl. 2), B61-B71 (2007).
30. Van Baren N, Brasseur F, Godelaine D et al.: Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94, 1156-1164 (1999). (Pubitemid 29380395)
31. Gure AO, Chua R, Williamson B et al.: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin. Cancer Res. 11(22), 8055-8062 (2005).
32. Mitchell MS: Cancer vaccines, a critical review - part I. Curr. Opin. Invest. Drugs 3(1), 140-149 (2002).
33. + T Cell responses to MAGE-3 protein in lung cancer patients. J. Immunology 172, 3289-3296 (2004).
34. Kensil CR, Soltysik S, Patel U et al.: Vaccines. Channock RM, Ginsburg HS, Brown F et al.: (Eds). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA 36-40 (1992).
35. + T cell responses to MAGE A3 protein in lung cancer patients. J. Immunol. 172, 3289-3296 (2004).
36. Atanackovic D, Altorki NK, Cao Y et al.: Booster vaccination of cancer patients with MAGE A3 protein reveals long-term immunological memory or tolerance depending on priming. PNAS 105, 1650-1655 (2008). (Pubitemid 351346569)
37. Kruit WHJ, van Ojik HH, Brichard VG et al.: Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE A3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 117(4), 596-604 (2005).
38. Marchand M, Punt CJ, Aamdal S et al.: Immunisation of metastatic cancer patients with MAGE A3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J. Cancer 39(1), 70-77 (2003). (Pubitemid 36005427)
39. Vantomme V, Dantinne C, Amrani N et al.: Immunologic analysis of a Phase I/II study of vaccination with MAGE A3 protein combined with the AS02B adjuvant in patients with MAGE-A3-positive tumors. J. Immunother. 27(2), 124-135 (2004). (Pubitemid 38282732)
40. Vansteenkiste J, Zielinski M, Linder A et al.: Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 25, 7554 (2007).
41. Kruit WH, Suciu S, Dreno B et al.: Immunization with recombinant MAGE A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group (16032-18031). 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clinical Oncology. 26(15S), 9065 (2008).
42. Bradbury PA, Shepherd PF: Immunotherapy for lung caner. J. Thoracic Oncol. 3, S164-S170 (2008).
43. Butts CM, Maksymiuk A, Goss G et al.: A multicentre Phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis. J. Thorac Oncol. S2, B1-01 (2007).